目前癌症免疫治疗使用活化的淋巴细胞-----淋巴细胞对肿瘤... - 中国病毒学论坛|我们一直在坚持！

Molecular cloning of interleukin-2(IL-2)has enabled adoptive cell therapy(ACT)to be established by using autologous activated lymphocytes. The low of regenerative medicine will promote the active development of ACT for public use, and ACTs that utilize tumor-infiltrating lymphocytes(TIL), in vitro tumor-sensitized lymphocytes, natural killer T cells, and gammadelta T cells are being evaluated as advanced medical treatments in Japan. In addition, chimeric antigen receptor genemodified T(CAR-T)cells and T cell receptor gene-modified T(TCR-T)cells are available for investigational clinical use. CART and TCR-T cells have been associated with serious adverse events as well as drastic clinical efficacies, indicating the importance of choosing the antigens to be targeted. Presently, it is accurate to state that lymphocytes do recognize cancer cells. Clinical ACT research focusing on TIL and mutated cancer antigens will be initiated for the development of personalized immunotherapy for cancer in the future.

因为白细胞激素2（IL2）的分子克隆，建立了使用自体活化的淋巴细胞这种过继细胞治疗方案。目前再生医学还处于低发展水平，ACT技术的快速发展会很快用于公众的使用。在日本，利用肿瘤浸润淋巴细胞（TIL）,体外肿瘤致敏淋巴细胞，自然杀伤细胞以及γδT细胞治疗被评为是先进的医疗技术。此外，嵌合抗原受体基因修饰的T（CAR-T）细胞和T细胞受体基因修饰的T细胞（TCR-T）也用于临床研究。CAR-T细胞治疗和TCR-T细胞治疗有着明显的治疗效果，然而会伴随着较为强烈的副反应，这也说明了选择靶向抗原的重要性。目前，可以明确的是，淋巴细胞能够准确识别癌症细胞。临床ACT研究集中在TILH和突变后的癌症抗原方面，这也开始了在将来使用个性化免疫方案治疗癌症。